Saintil Merline

Director Saintil Merline sells majority stake worth ~$1M, trimming position as stock reaches near 52-week highs amid strong recent momentum.

Director Saintil Merline liquidated more than half of her holdings in a single transaction, offloading roughly one million dollars worth of TD SYNNEX stock. The timing is noteworthy: the stock is trading essentially at its 52-week high after a sharp run-up, having gained significantly over both the past month and quarter. This is classic opportunistic selling—a director taking advantage of a peak to diversify, rather than a panic exit during weakness. TD SYNNEX remains operationally healthy with profitable operations and strong revenue growth, so the sale doesn't signal fundamental distress. However, the decision to reduce exposure this substantially right at the peak, combined with the stock's already stretched valuation, suggests Merline saw a window to lock in gains and decided to take it.

Director Saintil Merline sells 18,126 shares of RKLB at $75.04; stock down -25.8% from 52-week high, insider's recent RKLB sells preceded sharp declines.

Saintil Merline sold 18,126 shares at $75.04, reducing holdings by 6.5% to 261,903 shares. The timing pattern is noteworthy: his prior two RKLB sales (2026-01-14 and 2026-01-13) both preceded sharp 30-day declines of -25.1% and -23.8% respectively, and his cross-ticker sell history shows a 100.00% well-timed rate with an average 90-day return of -12.0%. The current price of $71.48 sits -25.8% from the 52-week high of $96.30, consistent with the pattern of declines following his prior recent transactions at this ticker. RKLB remains unprofitable with net income of $-18,257,000.00 against revenue of $155,080,000.00, though annual revenue growth stands at 38.0%. The sequence of insider sales immediately preceding multi-week selloffs warrants attention to whether subsequent market moves validate or contradict this pattern.

Director Saintil Merline sold 108,500 RKLB shares in 2 transactions for $9,436,680.00, reducing stake 27.9%

Saintil Merline, a director at Rocket Lab, executed 2 separate sales totaling 108,500 shares for $9,436,680.00 at an average blended price of $86.97, reducing his post-transaction holdings to 280,029 shares from 388,529 shares. The current stock price of $90.76 is 1.1% below the 52-week high of $91.80, and the stock has risen 63.6% over the past 30 days and 37.0% over the past 90 days—a significant uptrend period for this sale. Against his cross-ticker track record of 100.00% well-timed sell rate (with negative 90-day average returns of -12.0% post-sale), his single prior RKLB trade on 2024-11-26 followed that pattern with a 90-day return of -12.0%, suggesting consistent timing accuracy on this ticker. However, the company remains unprofitable on a full-year basis (net income of $-18,257,000.00) despite strong annual revenue growth of 78.3%, which provides context for director capital allocation decisions. The 27.9% reduction in holdings is material and occurs during a period of substantial stock appreciation.

Director Saintil Merline sold 50,000 shares of RKLB at $25.55 for $1.3M on 2024-11-26, near 52-week highs.

Director Saintil Merline sold 50,000 shares (a -10.4% reduction in holdings) at $25.55, coinciding with the stock trading within 0.0% of its 52-week high of $25.67. The stock has surged +128.0% over the prior 30 days and +312.0% over 90 days, recovering sharply from a 52-week low of $3.53. The sale occurs in a company with significant structural challenges: Rocket Lab posted a net loss of $-51,939,000.00 in its latest full fiscal year despite $104,808,000.00 in quarterly revenue and +15.9% annual growth, indicating operational unprofitability despite top-line expansion. The timing of the disposition during a steep rally and at elevated valuations, combined with the company's persistent losses, warrants investor attention to whether insiders view current levels as opportune for liquidation.